Supplemental Methods

**Cell Culture and reagents** - Mammary tissues from WT or p53 null mice were mechanically dissociated and placed in a digestion medium: DMEM supplemented with 200 U/ml collagenase (Sigma) and 100 U/ml hyaluronidase (Sigma) for 3 hours at 37°C. In order to obtain primary mammospheres, cells were plated onto ultra-low attachment plates (Falcon) at a density of 50,000 viable cell/ml (to obtain primary mammospheres) in a serum-free mammary epithelial basal medium (MEBM, BioWhittaker), supplemented with 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 2% B27 (Invitrogen), 20 ng/ml EGF and bFGF (BD Biosciences), and 4 µg/ml heparin (Sigma). Mammospheres were collected after 7 days and mechanically dissociated using a fire-polished pipette. For serial passage experiments, 1,000-5,000 cells from disaggregated primary-mammospheres were plated in ultra-low adherent 24-well plates in presence of methylcellulose (MethoCult™ SF M3236, Stem Cell Technologies) diluted 1:1 in MEBM complemented with cytokines. PKH26 (Sigma-Aldrich) staining was performed on mammospheres, as described (1).

For cell cycle analysis, SUM159PT were fixed in EtOH 70%, stained overnight with 50 µg/mL Propidium Iodide and 250 µg/mL RNaseA at 4°C, acquired using MACSQuant Flow cytometer (Miltieny) and analyzed by FlowJo software (TreeStar). For suspension mammosphere culture, SUM159PT were plated in low-adherent 150 mm dishes (pre-coated with poly-HEMA, Sigma Aldrich) at density of 1000 cells/ml in serum-free mammary epithelial medium (MEBM, Lonza) supplemented with 5 µg/ml insulin, 0.5 µg/ml hydrocortisone, 2% B27 (Invitrogen), 20 ng/ml EGF and human bFGF and 4 µg/ml heparin. For serial propagation, mammospheres were collected after 7 days of culture, enzymatically dissociated with trypsin-EDTA (0.025%) and plated at the same density for successive generations. For clonal mammospheres culture, 500 cells were plated in ultra-low adherent 24-well plates in presence of methylcellulose diluted 1:1 to stem medium (with 2x of growth factors).

For 3D Matrigel culture, 24-well plates were pre-coated with Matrigel (BD Biosciences, 120 µL/well) 15 minutes at 37°C. Cells were then seeded at 5,000 cells/well density and incubated for 14 days, medium was replenished every 2-3 days. L-Wnt3a ligand was produced using mouse fibroblast transfected with Wnt3a expressing vector as described (2).

**Transplantation experiments.** SUM159PT, previously infected with a lentiviral vector encoding luciferase (Addgene, #17477) and with pSlik34a, was injected in 6–8-week-old NSG female mice. For miR34a overexpression, mice were fed with doxycycline-containing food (625 mg kg⁻¹). Tumour growth was monitored weekly using caliper measurements. For measurements using IVIS Illumina System (Caliper Life Sciences), mice were injected by i.p. with D-luciferin (150 mg kg⁻¹) and imaged 15 min after injection. Animals were euthanized when the tumours were approximately 0.5–1 cm in the largest diameter. For all transplantation procedures, mice were anaesthetized with 2.5% avertin in PBS (100% avertin: 10 g of tribromoethanol in 10 ml of tertamyl alcohol [Sigma]). Cells were resuspended at the appropriate cell density in 14 µL PBS, 6 µL Matrigel® (BD Biosciences). For second passage transplantation assay, tumour cells were re-transplanted into NSG mice at limiting dilution, with no further treatment with doxy. TIC frequency was calculated with the Extreme Limiting Dilution Analysis (ELDA) web tool.

**ALDH assay.** ALDH activity was measured using Aldefluor Kit (Stem Cell Technologies #01700). Briefly, SUM159pPT were incubated for 45 min at 37°C with enzyme substrate (ALDEFLUOR reagent) or with an enzyme inhibitor (DEAB reagent), and cells were immediately FACS analyzed using MACSQuant Flow cytometer (Miltieny).
**Wnt-Reporter activity.** Sca\textsuperscript{low} or Sca\textsuperscript{high} cells transduced with Wnt reporter vector (7TF) were treated with L-Wnt3a and collected after 24 hours. For luciferase activity cells were lysed and assayed in multiple wells using the Dual-Luciferase Reporter Assay System (Promega) and a PHERAsstar FS plate reader.

**3’ UTR luciferase binding assays.** HEK293T cells were seeded at 10,000 cells per well in 96-well plate. After 24 h, cells were co-transfected with 100 ng of the indicated 3’ UTR reporter construct (pmiRGLO; Promega) and 40 nM of SCR or miRNA-34a mimics (QIAGEN) using Lipofectamine 3000 (Invitrogen), according to the manufacturer’s instructions. After 24 h, cells were lysed and assayed in quadruplicate wells for Firefly and Renilla luciferase activity using the Dual-Luciferase Reporter Assay System (Promega) and a PHERAsstar Plus plate reader. Firefly luciferase activity was normalized to Renilla luciferase activity for each transfected well as follows:

\[
\frac{\text{Firefly(miR)}}{\text{Renilla(miR)}} / \frac{\text{Firefly(SCR)}}{\text{Renilla(SCR)}}
\]

Data are representative of four independent experiments.

**Plasmids, virus production and infection**

**Plasmids**- Lentivirus for microRNA-34a precursors clone was purchased from System Biosciences (PMIRH34aPA-1) and the following sequence of precursor microRNA-34a was subcloned into the doxycycline-inducible pSLIK-Hygro (Addgene, #125737) vector:

GCCCTTATGGAGTGTGACTGTCTGGCTGGCTTTGAACTCCTGGCCTGAAGCGATCCTCCCACCTCGGCCCTCTGCATCTTCTTTCTCCTCCACATTTCTCTATATACAGAAACAGTTGTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

TGTTGTTGTTAGCAATAGTAAGGAAGCAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

GCCCAAGAGGGAAGATGAAAGCGAGACCGAGATGCCCAGACCCAGTGAGGAGACGCCAGAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

TGTTGTTGTTAGCAATAGTAAGGAAGCAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

GCCCAAGAGGGAAGATGAAAGCGAGACCGAGATGCCCAGACCCAGTGAGGAGACGCCAGAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

TGTTGTTGTTAGCAATAGTAAGGAAGCAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

GCCCAAGAGGGAAGATGAAAGCGAGACCGAGATGCCCAGACCCAGTGAGGAGACGCCAGAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

TGTTGTTGTTAGCAATAGTAAGGAAGCAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

GCCCAAGAGGGAAGATGAAAGCGAGACCGAGATGCCCAGACCCAGTGAGGAGACGCCAGAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

TGTTGTTGTTAGCAATAGTAAGGAAGCAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

GCCCAAGAGGGAAGATGAAAGCGAGACCGAGATGCCCAGACCCAGTGAGGAGACGCCAGAATCAGCAAGTGTTGCTGGGAGAGGCAGGACAGGGCTGTCCCCCGAGTCCCCTCCGGATGTCGTTTTGGCAGTGTCTTAGCTGGTTGTTGTGAGCAATAGTAAGGAAGCAATCAGCAAGTATAC

**Viruses production**- For lentiviral production, HEK293T cells were transfected in 15cm plate with: 10 μg of pRSV-Rev, 10 μg of pMDLG/pRRE (gag&pol), 10 μg of pMD2.G (VSV-G), and 20 μg of the lentiviral vector, 250 μl of 2M CaCl\textsubscript{2}, in a final volume of 2 ml TE 0.1X. The mix was added dropwise to 2 ml of 2X HBS, by bubbling, and then the calcium-phosphate precipitates were added to the cells at 70% of confluence. For virus concentration, supernatant was collected 36 h post-transfection, filtered through a 0.45 μm syringe-filter and ultracentrifuged for 2 h at 22000 rpm at 4°C. Viral pellet was resuspended in MEBM medium at 100X concentration. Viral stock was frozen (-80°C) or directly used to infect target cells at ratio: 10-30 μl virus/100,000 target cells in presence of 1μg/mL polybrene.

**IHC**- Mammary glands were fixed overnight in 4% formaldehyde at room temperature, embedded in paraffin, and sectioned (5μm). Sections were deparaffinized, subjected to antigen retrieval, and then incubated with antibody against Ki67 (rabbit, SP6, ThermoScientific, RM-9106-R7) and detected with MACH1 Universal HRP-Polymer Detection (Biocare Medical). Slides were counterstained with haematoxylin and finally mounted with Eukitt (Kindler GmbH). To assess the extent of the proliferative activity, the number of Ki67-positive cells were counted using 100X microscopic fields (microscope type) centered on mammary epithelial structures.
Immunofluorescence - Formalin-fixed paraffin-embedded mammary gland sections were stained with antibodies against Ki67 (rabbit, SP6, ThermoScientific, RM-9106-R7), K8 (rat, Troma-I, MABT329), SMA (mouse, Sigma-Aldrich, A5228). Images were acquired on a Leica TCS SP2 microscope equipped with a 63X oil-immersion objective lens (HCX Plan-Apochromat 63X NA 1.4 Lbd Bl; Leica).

Flow cytometry. Primary mammary epithelial cells from wild-type (WT) and miR-34TKO mice were stained with antibodies against CD49f (PerCP-Cy5.5, BioLegend; Pacific Blue, GoH3, 313617), CD61 (PE,2C9.G3; eBioscience, 12-0611-81), Epcam (APC, G8.8; eBioscience, 17-5791-80), lineage markers (biotinylated anti-CD45, -CD31, -Ter119 primary antibodies plus eFluor-450-conjugated streptavidin, 13-0451-85;13-0311-85;13-5921-85; ; and anti-CD45, -CD31 or -Ter119 with PE-Cy7; eBioscience 25-0451-82; 25-0311-82;25-5921-82). Cells infected with miR-sensor were stained with antibodies against NGFR (CD271-PeCy7; BD Pharmingen;562122). For Comma-Dβ cell line, cells were stained with antibodies against Sca-1 (with Pe-Cy7, D7; or PE, D7; eBioscience; 25-5981-82), CD24 (APC, M1/69; FITC, 30-F1, eBioscience;17-0242-82). SUM159PT cell lines were stained with antibodies against CD24 (PE, ML5; BD;555428). Cells were sorted at FACSaria II sorter or acquired using MACSQuant Flow cytometer (Milteny) and analysed using FlowJo software (TreeStar).

Evaluation of modality of SC mitotic division-WT mammospheres infected with Sensor-34a were mechanically dissociated and re-plated in mammary epithelial basal medium (MEBM, BioWhittaker). After 36-48 h, cells were recovered and transferred onto poly-D-lysine coated glass slides (Corning) and fixed with 4% paraformaldehyde. Cells were permeabilized with 0,1% Triton X-100 and stained with antibodies against CD49f (GoH3, ebioscience;555734) and Numb monoclonal antibody (Ab21). Confocal microscopy was performed on a Leica TCS SP2 microscope equipped with a 63X oil-immersion objective lens (HCX Plan-Apochromat 63X NA 1.4 Lbd Bl; Leica).

Transplantation Experiments-WT and miR-34TKO mammary cells were transplanted into the cleared fat pad of 3 week-old syngenic female mice. Transplanted mammary glands were collected 12 weeks after transplantation, fixed in a 4% formaldehyde and colored with carmine alum for whole mount staining (DeOme, 1959).

Whole Mount staining-Mammary glands were fixed in Ethanol/Acetic acid (3:1) and stained with carmine alum at room temperature overnight. Fat Pads were then clarified using BABB solution (Benzylalcohol/Benzylbenzoate 1:2). Images were analyzed at stereoscope.

RNA isolation and RT-qPCR Analysis-Total RNA was purified onto RNeasy columns (Qiagen) and treated on-column with DNase (Qiagen). For gene expression, cDNA was retro-transcribed using iSCRIPT reverse transcriptase (Biorad). Real-time RT-PCR was performed with FAST SYBR Green Master Mix (Applied Biosystems). Primer pairs were designed through computer assisted primer design software (Primer3). The complete list of primers used in this study is shown below.

| Primer Forward | Primer Reverse |
|----------------|----------------|
| mSlug1         | CTCACCTCGGGAGCATACAG GACCTACACGCCCAAGGATG |
| Gene      | Forward Sequence                  | Reverse Sequence                  |
|-----------|-----------------------------------|-----------------------------------|
| mp63∆dn   | CCTGGAAAAACATTGCCCGAGAC           | GAGGAGCCGTTCTGAATCTGC             |
| mSma      | TGATCACCATTTGAAAACGAAGC           | TGGTTTCGTGGA TGCCCGCT             |
| mKrt5     | GACTGAGGAGAGGGAGCAGA             | TCCAGCTGTCTACGGAGGTT             |
| mKrt14    | TGAGAGCCTCAAGGAGGAGGC            | TCTCCACATTGACGTCTCCAC           |
| mZeb1     | GTTCTGCAACACAGTTGTTTT            | GCTCAAGACTGTAAGTTGATG           |
| mTwist2   | CGCTACAGCAAGAAATCGAGC            | GCTGAGCTTGTGACAGAGGG            |
| mEsa      | GCTCTTCAAGCGCAAGCG               | GGTCGTAGGGGCTTTTCTCT            |
| mCdhl1    | CACCTGGAGAGAGGCCATGTC            | TGGGAACACATGACGAGCTCT            |
| mKrt8     | GCACTCAGGAGAGGAGCAG              | GGCAGAGGTGTGTGATGTAG             |
| mKrt18    | CTTGCTGGAGGATGGAGAAGGA          | CTGCCATCCACGATCTTCAGG            |
| mRpp0     | TTCATTGTGGGAGCAGAC              | TTTGTTGTAACACACAGGTATTGA         |
| hCDH2     | AGCCACCTTTAACTGAGGAGT            | GGCAAGTTGATTTGGAGGAGAT           |
| hVIMENTIN | GACGGCCATCAACACCCAGGTT          | CTTTGTGGTTGTTAGCTGGA            |
| hTFGA6    | ATGCAAGAGGATGCGATGTT             | TTCTCGGCTCTGATTAAACAGCT          |
| hKRT5     | AGGAGTTGGACCAGGTCAACAT          | TGGAGTGGAGCTTCACACTGC           |
| hKRT8     | CAGAAGTTCTCAAGGTTGTCAA         | CTCTGGTTGACCGTAACTGCG           |
| hKRT18    | TCGCAAAATACTGTGGACAATGC         | GCAGTGTGGATATTTGGGT            |
| hMUC1     | TGCCGCCGAAGAACTACAG             | TGGGTACTCGCTCATAAGGAT           |
| Pri-miR-34a| AGGACTTCTGGAAGCTCTTCTG        | AACTTCTCCACAGCACAAGGC            |
| Pri-miR-34b| TGCCATCAAAACAGCCACA          | TCCAGGGGCTACTGACTTCATAGG         |
| Pri-miR-34c| CTGAGCTCTCCTGTGAATCTCGT    | CTAAGGGCTACGGGTTCC              |
| hRpp0     | TTCATTGTGGGAGCAGAC              | CACGAGTTTCTCCAGAGC              |

- For miRNA expression, RNA were reverse transcribed by using miScript reverse transcription kit (QIAGEN) and RT-QPCR was performed using miScript SYBR Green PCR master mix (QIAGEN) and specific miScript primer assays.
**RNA seq.** Total RNA was extracted with the miRNeasy Mini (Qiagen) and treated on-column with DNase (Qiagen) and 1ug was purified with Ribozero rRNA removal kit (Illumina). Libraries were generated with the TruSeq RNA Library Prep Kit v2 (Illumina). Next, sequencing was performed on an Illumina HiSeq 2000 at 50 bp single-read mode and 50 million read depth (3x). RNA-seq NGS reads were aligned to the mm9 mouse or hg38 human reference genome using the TopHat aligner (version 2.0.6) with default parameters. Differentially expressed genes (DEGs) were identified using the Bioconductor package DESeq2 based on read counts, considering genes whose q value relative to the control is lower than 0.05 and whose maximum expression is higher than RPKM of 1. Data are deposited on GEO, GSE99401.

**Chromatin ImmunoPrecipitation (ChIP)-** ChIPs were performed as previously described (6). Briefly, cells were fixed in 1% formaldehyde for 10 min and resuspended in SDS buffer (50 mM Tris-HCl pH 8, 0,5% SDS, 100 mM NaCl, 5 mM EDTA, protease and phosphatase inhibitors). Cells were disrupted by sonication with a Branson 250 sonicator, performing 5 cycles of 30 sec 30% amplitude, yielding genomic DNA fragments with a bulk size of 100-400 bp. Samples were immunoprecipitated overnight at 4°C with 10 µg p53 antibody (NCL-p53-CM5p - Novocastra laboratories). DNA was then purified by Qiaquick columns (Qiagen) and amplified by RT-qPCR with FAST SYBR Green Master Mix (Applied Biosystems). The following primers were used:

| miR-34a | Primer Forward | Primer Reverse |
|---------|----------------|----------------|
| CAGCCTGGAGGAGGATCGA | TCCCAAGGCCAAAATCT |
AGO2 RNA immunoprecipitation

AGO2 RNA immunoprecipitation (AGO2-RIP) experiments were conducted with the Imprint RNA Immunoprecipitation Kit (Sigma-Aldrich), according to manufacturer’s instructions. Briefly, cells were treated with doxycycline (2ug/ml) for 24 hours in order to induce miR-34a expression. A total of 5 million cells were used for each RIP experiment. Cells were trypsinized, collected in a tube and washed twice with ice cold PBS. Cells were resuspended in 200 µl of lysis buffer [mild lysis, protease inhibitor cocktail (PIC), ribonuclease inhibitor] and incubated on ice 15'. Cell debris was removed by centrifugation at 16,000g, 10 min at 4°C. A fraction (10%) supernatant was collected as ‘input’ and stored on ice, while the remainder was used for immunoprecipitation. For each RIP, 20 µl of magnetic beads with Protein A were pre-cleared with 200 ul of Wash Buffer on a magnetic stand and, then, mixed with 5 µg of control antibody (rabbit Anti-Rat IgG) or Anti-AGO2 antibody (mouse monoclonal 2A8 clone by Sigma Aldrich - Cat. Num. SAB4800048) at RT with rotation for 30 min. 5 µg rat IgG or monoclonal Anti-AGO2 antibody were added to the magnetic beads. Samples were washed twice with 0.5 mL of wash buffer, before adding cell lysates (supernatant) and incubating samples at 4°C with rotation overnight. Samples were then separated with the magnetic stand, washed five times (0.5 ml wash buffer, each time) and, finally, resuspended in 0.2 ml of wash buffer. RNA extractions from RIP samples were performed with 0.6 ml (1:3 ratio) of TRIzol LS (Life Technologies; Cat. Num 10296-028) followed by purification on micro RNeasy Micro Kit columns.

ELDA Software- Limiting dilution analysis was performed using the Extreme Limiting Dilution Analysis (ELDA) web tool (http://bioinf.wehi.edu.au/software/elda/) (7). ELDA computes a 95% confidence interval for the active cell frequency in each population group and it implements a likelihood ratio test for the acceptance of the single-hit hypothesis (pvalue).

Supplemental References

1. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giuliani B, Brisken C, Minucci S, Di Fiore PP, and Pelicci PG. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell. 2009;138(6):1083-95.
2. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, Reya T, Yates JR, 3rd, and Nusse R. Wnt proteins are lipid-modified and can act as stem cell growth factors. Nature. 2003;423(6938):448-52.
3. Brown BD, Gentner B, Cantore A, Colleoni S, Amendola M, Zingale A, Baccarini A, Lazzari G, Galli C, and Naldini L. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol. 2007;25(12):1457-67.
4. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L, Jaenisch R, and Jacks T. Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A. 2004;101(28):10380-5.
5. Insinga A, Monesiroli S, Ronzoni S, Carbone R, Pearson M, Pruner G, Viale G, Appella E, Pelicci P, and Minucci S. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. *EMBO J.* 2004;23(5):1144-54.

6. Tonelli C, Morelli MJ, Bianchi S, Rotta L, Capra T, Sabo A, Campaner S, and Amati B. Genome-wide analysis of p53 transcriptional programs in B cells upon exposure to genotoxic stress in vivo. *Oncotarget.* 2015;6(28):24611-26.

7. Hu Y, and Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *Journal of Immunological Methods.* 2009;347(1,Äi2):70-8.
Supplementary Figure 1 (related to Figure 3). Loss of miR-34 affects mammary gland biology. (a) Immunohistochemical analysis of p53-null mammary glands section by Ki67 (proliferation marker) and counterstained with haematoxylin. Scale bar, 100 μm. (b) Immunofluorescence staining of WT, 34TKO and p53-null mammary gland by Ki67, keratin 8 (K8) and smooth muscle actin (SMA) as luminal and basal/myoepithelial markers, respectively. Scale bar, 10 μm. (c) Growth curve of WT, miR-34TKO and p53-null mammospheres. Cells were plated in triplicate at M1 passage and counted after 7 days. Serial re-plating of mammospheres was performed, and cell numbers were calculated at each passage. The average and SD of triplicate experiments are shown. (d) FACS analysis of WT, miR-34TKO and p53-null mammospheres at M4. Mammospheres were dissociated and stained with antibodies against CD49f and CD61. (e) Representative pictures of carmine-stained whole mount of mammary outgrowths obtained after transplantation of WT and miR-34TKO mammary epithelial cells into syngenic mice. Scale bar, 1 mm. (f) Frequency of the outgrowths upon limiting cell dilutions. MaSC-frequency was calculated with Extreme Limiting Dilution Analysis (ELDA) web tool.
Supplementary Figure 2 (related to Figure 4). MiR34a controls fate commitment and proliferation of progenitor cells by modulating different pathways. (a) Representative dot plot of the CommaDβ cell line stained with antibodies against Sca-1 and CD24, showing the different levels of Sca-1 (Scahigh, Scalow). (b) Levels of basal/mesenchymal, luminal/epithelial and EMT genes in Scahigh compared to Scalow cells (log2 fold-change). The average and SD of triplicate independent experiments are shown. (c) Morphology of the Scahigh and Scalow cells plated in 2D (left) and organoids plated in 3D Matrigel (right) conditions after FACS-sorting. (d) Representative dot plots of CommaDβ infected with sensor-SCR and sensor-34a. Sca-1 and GFP levels of cells that expressed similar amount of ∆NGFR are shown. Scalow cells infected with sensor-34a showed reduced GFP levels. (e) Representative dot plots of FACS-sorted Scalow cells stained with antibodies against Sca-1 and CD24 at different days (from day 6 to day 24) in culture; a significant portion of Scalow cells progressively converts to Sca-high (red-dashed lines).
Supplementary Figure 3 (related to Figure 4). MiR34a controls fate commitment and proliferation of progenitor cells by modulating different pathways. (a) Principal Component Analysis (PCA) for individual samples from the RNA-seq analysis of CommaDB, divided into 4 groups: Sca high, Sca low, Sca high pSlik34a NT and doxycyclin-induced (34a) samples. (b) Histogram summarizing the results of the gene set enrichment analysis (mSigDB) performed with the Hallmark Signature using as input the Sca high DEGs. (c) As in (a) but showing the histogram summarizing the results using as input the miR-34a DEGs. (d) Seed enrichment analysis at 3’ UTR sequences of miR-34a expression profile by Sylamer (1). The input list consisted of all expressed genes in the Sca dataset (N = 9031), ordered from the most downregulated to the most upregulated 3′ UTR upon miRNA expression. The two most over-represented motifs correspond to the canonical miR-34a 7mers (7mer-1A and 7mer-m8, as indicated at the top of the panel). (e) Contingency analysis between miR-34a regulated genes [distinguished in upregulated (UP), downregulated (DN), not regulated (no reg)] and targets predicted by either miRanda (top panel) or TargetScan (bottom). Shown the significance of the distribution by the likelihood ratio test (JMP) in the all classes (miRanda Chi2=58.01, P < 0.001; TScan Chi2=77.2, P < 0.001), or just for downregulated target genes (YES; miRanda Chi2=28, P < 0.001; TScan Chi2 = 46, P < 0.001) are given.
Supplementary Figure 4 (related to Figure 5). MiR-34a controls Wnt signaling in mammary epithelial cells.

(a,b) Conversion of Scalow into Scahigh cells observed by FACS upon L-Wnt3a treatment from day 1 to day 26 after treatment. Average and SD of two independent experiments are shown. (c,d) Wnt signaling activation measured by a Wnt-reporter (7-TCF-luciferase) upon miR-34a knockdown (ZIP34a) on Sca^low^ cells in basal conditions (c) or upon ligand stimulation (L-Wnt3a; 24 h) (d). The average and SD of four or five experiments, respectively, are shown. (e) RNA immunoprecipitation (RIP) of Ago2 bound miRNAs in SCA^high^ cells in basal conditions (NT) or upon miR-34a overexpression (+doxy, 24h). (f) Distribution of the normalized sphere area of WT and miR-34TKO (34TKO) mammospheres at M3 passage reported upon L-Wnt3a treatment. (g) Distribution of luminal versus basal cell ratio in the mammary glands of 6–8-week-old WT and MMTV-Wnt1 (Wnt) mice. (h) Distribution of luminal versus basal cell ratio in the tumour sections of Wnt/wt and Wnt/34TKO. Representative images of Wnt/wt and Wnt/34TKO tumour sections stained for keratin (K)14 and K8 antibodies are shown in panel (i). Scale bar, 100 μm.
Supplementary Figure 5 – related to Figure 6- miR-34a reduces Cancer Stem Cells in vitro and in vivo

(a) Levels of miR-34a in a panel of primary tumours (high grade tumours (G3-ER-) vs. low grade tumours (G1-ER+)) from IEO hospital. RNA was extracted from FFPE sections and evaluated by RT-qPCR. (b) Levels of miR-34a in SUM159PT pSlik34a treated with doxycycline for 14 days and after doxycycline removal (10 days doxy + 4 days washout; (doxy washout)). (c) SUM159PT cells were chronically exposed to miR-34a overexpression and the expression of CD24 was measured by FACS analysis at different days. Representative histogram plots at different days of treatment are shown. (d,e) Distribution of the normalized sphere area of SUM159PT mammospheres over-expressing miR-34a (+doxy) and after doxycycline removal (doxy washout). (f) The expression levels of selected miR-34a targets within the Wnt signaling pathways are shown. Left panel, levels of the genes in human breast cancer cell lines grouped according to molecular subtypes: Luminal, Her2+ER+, Triple negative basal-like [TNBC; (basal)], Triple negative mesenchymal-like [TNBC; (mes_like)]. Shown also the expression of miR-34a in the same samples. A P-value (non-parametric, Dunnet's Methods comparison) between basal and mesenchymal TNBC samples is also shown. Right panel, levels of the genes in human ER- breast cancers (TCGA dataset) with different (high vs. low) EMT-score. P-value (Wilcoxon test) is given.
Supplementary Figure 6 – related to Figure 6- miR-34a reduces Cancer Stem Cells in vitro and in vivo (a) SUM159PT cells infected with pSlik34a and LUC were injected into NSG mice and let tumour grow 2 weeks, then fed with doxy or normal food for three weeks. Tumours were monitored using IVIS imaging system. (b,c) miR-34a overexpression (+doxy) significantly reduces tumour growth (b) and tumour weight (c). Tumour size was determined using the formula: \((W^2 \times L) / 2\), where W is width and L is length.
| Symbol   | Type of reg | Function          | Human Ref.seq.   | Mouse Ref.seq. | Reference          | MRE (mouse) | Validation (CommaDB) | Validation (Mammosph.) | MRE (human) | Validation (SUM+doxy) |
|----------|-------------|-------------------|------------------|----------------|--------------------|-------------|----------------------|------------------------|-------------|------------------------|
| WNT1     | positive    | ligand            | NM_005430        | NM_053116      | Kim,2011           | yes         | NE                   | NE                     | yes, validated | X                      |
| WNT3     | positive    | ligand            | NM_030753        | NM_009521      | Kim,2011           | yes         | NE                   | NE                     | yes          | X                      |
| WNT4     | positive    | ligand            | NM_030761        | NM_009523      | new target         | yes         | NO?                  | X                      | X            |            |
| WNT10a   | positive    | ligand            | new target       | yes            |                     |             |                      |                        |              |                        |
| LRP6     | positive    | receptor          | NM_002336        | NM_008514      | Kim,2011           | yes         | NO                   | NO                     | yes, validated | X                      |
| FZD1     | positive    | co-receptor       | NM_007197        | NM_175284      | new target         | yes, validated | X                   | X                      | yes          | X                      |
| FZD2     | positive    | co-receptor       | NM_001466        | NM_020510      | new target         | yes, validated | X                   | X                      | X            | NO                     |
| NOTUM    | negative    | antagonist/ligand | NM_178493        | NM_175263      | new target         | yes         | X                   | X                      | yes          | X                      |
| IGFBP5   | negative    | antagonist/receptor| NM_000599        | NM_010518      | new target         | yes         | X                   | X                      | yes          | X                      |
| PIP5K1A  | positive    | kinase            | NM_003557        | NM_008847      | new target         | yes, validated | X                   | X                      | yes, validated | X                      |
| BCL9L    | positive    | co-activator      | NM_182557        | NM_030256      | new target         | yes         | X                   | X                      | yes          | X                      |
| BCAT     | positive    | trancriptional co-activator | NM_001904 | NM_001165902 | Kim,2011,Cha,2014 | NO         | NO                   | NO                     | yes          | NO                     |
| LEF1     | positive    | transcription factor| NM_016269 | NM_010703      | Kim,2011,Cha,2014 | yes       | NE                   | NO?                    | yes, validated | X                      |
| AXIN2    | negative    | degradation complex| NM_004655        | NM_015732      | Cha,2014           | NO         | NO                   | NO                     | yes          | NO                     |
| CD44     | negative    | target gene       | NM_001001392     | NM_001039151   | Siemens,2011       | NO         | NO                   | yes, validated        | X            | NO                     |
| GROUP       | cell line          | subtype       | dct (U6-miR-34) | log2 FC  |
|-------------|--------------------|---------------|-----------------|---------|
| 1. NORM     | HMLE               | 1. NORM       | 3.63            | 1.559950233 |
| 1. NORM     | MCF-10A            | 1. NORM       | 4.91            | 0.641046067  |
| 2. Lum      | MCF7               | 2. Lum        | 4.07            | 1.149301154  |
| 2. Lum      | BT-483             | 2. Lum        | 2.74            | 2.890605639  |
| 2. Lum      | MDA-MB-175-VII     | 2. Lum        | 2.72            | 2.929028068  |
| 2. Lum      | HCC1428            | 2. Lum        | 4.78            | 0.704926465  |
| 2. Lum      | MDA-MB-41S         | 2. Lum        | 3.71            | 1.475802846  |
| 2. Lum      | T-47D              | 2. Lum        | 2.72            | 2.940279653  |
| 3. HER2 (lum) | SK-BR-3           | 3. HER2 (lum) | 2.47            | 3.492255576  |
| 3. HER2 (lum) | ZR-75-30          | 3. HER2 (lum) | 2.12            | 4.435614884  |
| 3. HER2 (lum) | MDA-MB-361        | 3. HER2 (lum) | 3.43            | 1.79599438   |
| 3. HER2 (lum) | UACC-812          | 3. HER2 (lum) | 2.82            | 2.732737449  |
| 3. HER2 (lum) | HCC1954           | 3. HER2 (lum) | 2.59            | 3.218593491  |
| 3. HER2 (lum) | HCC2218           | 3. HER2 (lum) | 0.87            | 10.53394542  |
| 3. HER2 (lum) | HCC1419           | 3. HER2 (lum) | 1.52            | 6.736597054  |
| 3. HER2 (lum) | BT474             | 3. HER2 (lum) | 3.82            | 1.369559398  |
| 4. TNBC     | HCC1569            | 4. TNBC       | 4.14            | 1.092307807  |
| 4. TNBC     | BT20               | 4. TNBC       | 6.96            | 0.154975913  |
| 4. TNBC     | MCF10A_DCIS        | 4. TNBC       | 3.62            | 1.566414884  |
| 4. TNBC     | MDA-MB-453         | 4. TNBC       | 2.70            | 2.968563014  |
| 4. TNBC     | MDA-MB-468         | 4. TNBC       | 4.34            | 0.953628993  |
| 4. TNBC     | DU4475             | 4. TNBC       | 3.27            | 2.003492019  |
| 4. TNBC     | HCC1143            | 4. TNBC       | 7.10            | 0.140308079  |
| 4. TNBC     | SUM149             | 4. TNBC       | 8.39            | 0.057551103  |
| 4. TNBC     | HCC1937            | 4. TNBC       | 4.51            | 0.848826973  |
| 4. TNBC     | BT549              | 5. TNBC       | 8.15            | 0.067961528  |
| 4. TNBC     | MDA-MB-231         | 5. TNBC       | 10.45           | 0.013846841  |
| 4. TNBC     | SUM159             | 5. TNBC       | 7.80            | 0.086802025  |
| 4. TNBC     | MDA-MB-436         | 5. TNBC       | 9.40            | 0.028672513  |
| 4. TNBC     | Hs 578T            | 5. TNBC       | 9.16            | 0.03381968   |
| N  | GENE SIGNATURE (SUM_34a_Prolif_Arrested) | GS DETAILS | SIZE | ES  | NES  | NOM p-val | FDR q-val |
|----|----------------------------------------|------------|------|-----|------|-----------|-----------|
| 1  | HALLMARK_E2F_TARGETS                   | Details ...| 198  | -0.58 | -2.84 | 0         | 0         |
| 2  | HALLMARK_G2M_CHECKPOINT                | Details ...| 196  | -0.53 | -2.49 | 0         | 0         |
| 3  | HALLMARK_MYC_TARGETS_V2                | Details ...| 57   | -0.64 | -2.47 | 0         | 0         |
| 4  | HALLMARK_NOTCH_SIGNALING               | Details ...| 26   | -0.49 | -1.6  | 0.02      | 0.017     |
| 5  | HALLMARK_WNT_BETA_CATENIN_SIGNALING    | Details ...| 31   | -0.43 | -1.49 | 0.021     | 0.033     |
| 6  | HALLMARK_MYC_TARGETS_V1                | Details ...| 199  | -0.26 | -1.27 | 0         | 0.137     |
| 7  | HALLMARK_APICAL_SURFACE                | Details ...| 19   | -0.36 | -1.08 | 0.351     | 0.412     |
| 8  | HALLMARK_MITOTIC_SPINDLE               | Details ...| 187  | -0.18 | -0.86 | 0.92      | 1         |
| 9  | HALLMARK_SPERMATOGENESIS               | Details ...| 53   | -0.2  | -0.76 | 0.911     | 1         |
| 10 | HALLMARK_DNA_REPAIR                    | Details ...| 134  | -0.13 | -0.58 | 1         | 0.994     |

| N  | GENE SIGNATURE (SUM_34a_Prolif_Recovered) | GS DETAILS | SIZE | ES  | NES  | NOM p-val | FDR q-val |
|----|------------------------------------------|------------|------|-----|------|-----------|-----------|
| 1  | HALLMARK_BILE_ACID_METABOLISM            | Details ...| 68   | -0.32 | -1.28 | 0.075     | 0.444     |
| 2  | HALLMARK_WNT_BETA_CATENIN_SIGNALING      | Details ...| 31   | -0.35 | -1.16 | 0.248     | 0.512     |
| 3  | HALLMARK_NOTCH_SIGNALING                 | Details ...| 26   | -0.32 | -1.04 | 0.398     | 0.747     |
| 4  | HALLMARK_XENOBIOTIC_METABOLISM           | Details ...| 126  | -0.23 | -1.02 | 0.41      | 0.622     |
| 5  | HALLMARK_PI3K_AKT_MTOR_SIGNALING         | Details ...| 84   | -0.21 | -0.87 | 0.796     | 0.92      |
| 6  | HALLMARK_SPERMATOGENESIS                 | Details ...| 53   | -0.19 | -0.75 | 0.881     | 0.94      |
| FWER p-val | RANK AT MAX | LEADING EDGE |
|------------|-------------|--------------|
| 0          | 3135        | tags=62%, list=29%, signal=86% |
| 0          | 2441        | tags=49%, list=23%, signal=62% |
| 0          | 3127        | tags=77%, list=29%, signal=108% |
| 0.051      | 513         | tags=19%, list=5%, signal=20% |
| 0.12       | 322         | tags=16%, list=3%, signal=17% |
| 0.495      | 7856        | tags=99%, list=73%, signal=354% |
| 0.909      | 1532        | tags=37%, list=14%, signal=43% |
| 1          | 1812        | tags=19%, list=17%, signal=23% |
| 1          | 3155        | tags=38%, list=29%, signal=53% |
| 1          | 1630        | tags=12%, list=15%, signal=14% |

| FWER p-val | RANK AT MAX | LEADING EDGE |
|------------|-------------|--------------|
| 0.58       | 1132        | tags=21%, list=10%, signal=23% |
| 0.863      | 294         | tags=13%, list=3%, signal=13% |
| 0.979      | 1843        | tags=38%, list=17%, signal=46% |
| 0.985      | 1203        | tags=16%, list=11%, signal=18% |
| 1          | 2250        | tags=24%, list=21%, signal=30% |
| 1          | 1484        | tags=21%, list=14%, signal=24% |